

NOVARTIS ACCESS-TO-MEDICINE PROJECTS 2008

Project	Objective	Target region	Value (USD millions)	Patients
Malaria/WHO ¹	Provide <i>Coartem</i> at cost for public sector use	Africa, Asia, Latin America	263	70 000 000
Leprosy/WHO ²	Eliminate leprosy by providing free medications to all patients worldwide with WHO, through 2010	Global	7	340 000
Tuberculosis ²	Donation of fixed-dose combinations	Tanzania, Sri Lanka	1	44 000
Fascioliasis ³	Providing free of charge <i>Egaten</i> to treat patients that are infected with Fascioliasis	Peru, Yemen	0.3	212 000
Novartis Foundation for Sustainable Development (NFSD) ⁴	Improve health and quality of life of poor people in developing countries through think tank, policy and project work	Developing countries	9	3 002 000
Novartis Institute for Tropical Diseases (NITD) ⁴	Discover novel treatments and prevention methods for major tropical diseases; NITD discoveries to be available in poor endemic countries without profit	Developing countries	14	–
Novartis Vaccines Institute for Global Health (NVGH) ⁴	To develop effective and affordable vaccines for neglected infectious diseases of developing countries	Developing countries	4	–
US patient assistance program (PAP) ² (excl. <i>Gleevec</i>)	Assistance to patients experiencing financial hardship, without third-party insurance coverage for their medicines	United States	107	81 000
<i>Gleevec</i> US PAP ²	Within capability of Novartis, continue to ensure access for patients in the US who cannot afford the drug	United States	77	4 000
<i>Glivec</i> Global PAP ^{2,5}	Within capability of Novartis, continue to ensure access for patients outside the US who cannot afford the drug	Global (excluding US)	751	23 000
Together Rx Access	Discount program for the uninsured	United States	0.4	7 000
Emergency relief & other product donations	Support to humanitarian organizations	Global	25	–
Total			1 259	73.7 million

¹During 2008, 70 million *Coartem* treatments reached patients based on a preliminary analysis of local distribution; Of these, 30.2 million treatments came from shipments completed in 2007, and 39.8 million from the total shipment of 73.8 million treatments completed in 2008. The value of the *Coartem* program in 2008 was calculated using the number of treatments shipped in 2008 and the ex-factory price of *Coartem* to private-sector purchasers in malaria-endemic developing countries, minus payments to Novartis to cover costs under terms of the public-private partnership with WHO. These payments were received through WHO, UNICEF and other procurement agencies, acting on behalf of governments and other public-sector institutions in developing countries eligible to receive *Coartem* at the not-for-profit price.

²Ex-factory price to private market

³At manufacturing costs

⁴Novartis operating costs

⁵Value includes donations under shared contribution and co-pay models, whereas patients in shared contribution and co-pay models are not included in the number of patients reached